Literature DB >> 26925880

Breath Testing for Small Intestinal Bacterial Overgrowth: A Means to Enrich Rifaximin Responders in IBS Patients?

Amit Gupta1, William D Chey1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26925880     DOI： 10.1038/ajg.2016.32

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  5 in total

1.  Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference.

Authors:  A Gasbarrini; G R Corazza; G Gasbarrini; M Montalto; M Di Stefano; G Basilisco; A Parodi; P Usai-Satta; P U Satta; P Vernia; C Anania; M Astegiano; G Barbara; L Benini; P Bonazzi; G Capurso; M Certo; A Colecchia; L Cuoco; A Di Sario; D Festi; C Lauritano; E Miceli; G Nardone; F Perri; P Portincasa; R Risicato; M Sorge; A Tursi
Journal:  Aliment Pharmacol Ther       Date:  2009-03-30       Impact factor: 8.171

Review 2.  Breath testing for small intestinal bacterial overgrowth: maximizing test accuracy.

Authors:  Richard J Saad; William D Chey
Journal:  Clin Gastroenterol Hepatol       Date:  2013-10-01       Impact factor: 11.382

3.  Rifaximin therapy for patients with irritable bowel syndrome without constipation.

Authors:  Mark Pimentel; Anthony Lembo; William D Chey; Salam Zakko; Yehuda Ringel; Jing Yu; Shadreck M Mareya; Audrey L Shaw; Enoch Bortey; William P Forbes
Journal:  N Engl J Med       Date:  2011-01-06       Impact factor: 91.245

Review 4.  The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis.

Authors:  Stacy B Menees; Monthira Maneerattannaporn; Hyungjin Myra Kim; William D Chey
Journal:  Am J Gastroenterol       Date:  2011-11-01       Impact factor: 10.864

Review 5.  Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.

Authors:  Hoonmo L Koo; Herbert L DuPont
Journal:  Curr Opin Gastroenterol       Date:  2010-01       Impact factor: 3.287
  5 in total
  7 in total

1.  It is Time to Re-Think the Role of Small Intestinal Bacterial Overgrowth in IBS Patients.

Authors:  Edoardo Savarino; Manuele Furnari; Andrea Ottonello; Vincenzo Savarino
Journal:  Am J Gastroenterol       Date:  2016-09       Impact factor: 10.864

2.  Value-based Pricing for Rifaximin Increases Access of Patients With Irritable Bowel Syndrome With Diarrhea to Therapy.

Authors:  Eric D Shah; Sameer D Saini; William D Chey
Journal:  Clin Gastroenterol Hepatol       Date:  2019-03-01       Impact factor: 11.382

Review 3.  Use of rifaximin in gastrointestinal and liver diseases.

Authors:  Rani H Shayto; Rachel Abou Mrad; Ala I Sharara
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

Review 4.  Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders.

Authors:  Hyo Jeong Lee; Jong Kyoung Choi; Han Seung Ryu; Chang Hwan Choi; Eun Hee Kang; Kyung Sik Park; Yang Won Min; Kyoung Sup Hong
Journal:  J Neurogastroenterol Motil       Date:  2017-01-30       Impact factor: 4.924

Review 5.  Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth.

Authors:  L Gatta; C Scarpignato
Journal:  Aliment Pharmacol Ther       Date:  2017-01-12       Impact factor: 8.171

Review 6.  The gut microbiome and irritable bowel syndrome.

Authors:  Stacy Menees; William Chey
Journal:  F1000Res       Date:  2018-07-09

7.  Effect of Dietary Paeoniae Radix Alba Extract on the Growth Performance, Nutrient Digestibility and Metabolism, Serum Biochemistry, and Small Intestine Histomorphology of Raccoon Dog During the Growing Period.

Authors:  Jing Wang; Guangyu Li; Wei Zhong; Haihua Zhang; Qianlong Yang; Lihong Chen; Jinming Wang; Xuewen Yang
Journal:  Front Vet Sci       Date:  2022-04-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.